Country Managing Director — Specialist-Clinics Portfolio

The mandate

A multinational-owned specialist-clinics portfolio intends to expand its UK country franchise, but the board will not approve the next site wave until patient-safety controls operate consistently across existing clinics. Local medical leaders have strong professional practices, yet incident escalation, consent evidence, emergency transfer and post-procedure contact differ. A planned new Country Managing Director will unite growth authority with operating accountability.

Approximately 675 employees and material partners support consultations, diagnostics, procedures and recovery across London and the wider United Kingdom. The Managing Director owns the country P&L, clinics, workforce, capital, commercial delivery and leadership team, reporting to the Group board and Group Chief Executive. Medical directors retain professional governance and independent clinical decisions.

The first obligation is a country control baseline. The leader will examine actual cases across specialties, distinguishing universal controls from procedure-specific requirements. Consent, identity, medication, deterioration, transfer and follow-up need owners, source evidence and escalation thresholds. A clinic's historical reputation will not exempt it from common assurance.

Growth cases must demonstrate that controls will scale. A new site requires credentialled practitioners, supervision, emergency arrangements, equipment readiness, pharmacy or diagnostic interfaces and secure record access before the first patient. Opening-date pressure cannot convert incomplete readiness into an accepted operational risk without explicit board authority.

Medical-practitioner relationships need country consistency. Consultants may be employed, contracted or practising under privileges. Credentialling, scope, peer review and concern management will use one governance spine while respecting legal distinctions. Commercial contribution cannot influence clinical standing, and local executives must know when an issue leaves their discretion.

Emergency transfer arrangements are a particular focus. Some clinics depend on local relationships that have never been tested under peak conditions. The Managing Director will ensure each service has a clinically agreed trigger, receiving route, transport plan, accompanying information and post-event review. Simulations should include unavailable contacts and communications failure.

Post-procedure continuity extends beyond discharge. Patients need understandable instructions, response access and ownership of outstanding results. The country model will track whether follow-up occurs, not merely whether it was scheduled. Language, disability and digital access must be accounted for in communication design.

Workforce growth will be paced by competence. Recruitment plans should identify scarce theatre, recovery, diagnostic and coordination skills, with supervision capacity treated as a constraint. The Managing Director will build internal development and cross-clinic learning rather than assume every new site can recruit an experienced team independently.

The economic model will include control costs. Emergency cover, quality staffing, equipment maintenance, training and clinical system integration are not overheads to remove from an investment case. The leader will work with finance on procedure and clinic economics that capture cancellation, rework and underutilised ramp capacity.

Procurement needs clinical and operational governance. Standardising consumables and equipment can improve resilience, but substitutions require authorised evaluation and training. The Managing Director will not permit a group price agreement to create an unassessed change in clinical practice. Supplier performance will include availability, traceability and response.

Patient feedback and complaints should influence design. Current classifications emphasise service dissatisfaction while clinical signals may sit inside narrative. The leader will introduce multidisciplinary review and ensure complainants receive a timely, candid response. Trends should inform training, scheduling and investment, not remain within customer service.

The country executive team must operate collectively. Clinic, medical, nursing, finance, people, quality and commercial leaders will carry shared objectives for safe growth. The Managing Director will decide unresolved trade-offs and ensure issues reach the board early. Consensus cannot become a reason to postpone action.

Expansion sequencing will follow evidence. Clinics that demonstrate control maturity and leadership depth can sponsor new openings; fragile locations must recover before exporting their model. The leader will state what would pause a launch and protect that authority when sunk costs or public commitments create pressure.

What you will own

• UK country P&L, clinics and growth sequence.
• Common patient-safety controls with clinical leaders.
• Site readiness, opening and pause decisions.
• Practitioner governance and country leadership.
• Emergency transfer and post-procedure continuity.
• Workforce capability, capital and supplier readiness.
• Patient feedback and regulatory relationships.
• Country succession and licence to grow.

The first 12 months

In the first 45 days, review high-risk pathways, test clinic control evidence and identify any service operating without dependable emergency or follow-up arrangements. Agree immediate safeguards and a country control standard.

By month six, complete readiness assessment for the proposed expansion, standardise priority controls and run live simulations at every procedure site. Confirm the workforce and capital sequence.

At twelve months, achieve 98% complete evidence for priority controls, reduce overdue post-procedure follow-up by 70% and close 90% of serious-review actions by agreed dates with effectiveness verification. Every clinic should pass an unannounced emergency-transfer exercise, while the approved growth plan meets country return thresholds including full safety costs.

What the board will examine

• Control consistency across different specialties and clinics.
• Growth openings gated by real operating readiness.
• Practitioner contribution separated from clinical standing.
• Transfers and follow-up working under adverse conditions.
• Expansion economics including safety infrastructure.
• Executives escalating weaknesses before external scrutiny.

The person

You bring 28+ years in healthcare, including country managing director, chief operating or portfolio CEO responsibility across regulated specialist clinics. Your evidence includes site openings, patient-safety governance, practitioner relationships and full P&L authority in the United Kingdom.

The board expects an operator who can protect growth by slowing it when readiness is incomplete. You should have worked directly with clinical regulators, payers and senior medical leaders. This permanent position is onsite in London, with regular presence across the clinic portfolio.

Compensation and terms

Base compensation is GBP 350,000–520,000 plus annual incentive and long-term participation linked to safe growth, country contribution, control maturity, patient continuity and leadership. The permanent appointment is onsite in London and reports to the Group board and Group Chief Executive. Planned timing allows the appointee to shape the next growth decision.

Confidentiality

The portfolio, clinics, practitioners, patients, incidents, regulators, expansion locations and financial cases are confidential. Detail is disclosed after fit, conflict and confidentiality checks. Applicants must not contact possible clinic groups or practitioners to establish the client identity.